|
|
Post by ktim on Mar 8, 2024 12:59:55 GMT -5
Does Inhale-3 protocol allow/suggest/require follow up doses as needed?
|
|
|
|
Post by mytakeonit on Mar 8, 2024 13:02:33 GMT -5
sayhey ... find my house because my daughter and bf drink expensive bourbon.
But, that's my$$$takeonit
|
|
|
|
Post by sayhey24 on Mar 8, 2024 13:04:29 GMT -5
Does Inhale-3 protocol allow/suggest/require follow up doses as needed? Thats what it says - lets hope they do corrections The Afrezza-Degludec group will inhale Afrezza at meals and corrections and will inject insulin degludec once a day for the 17 weeks of the RCT Phase. Dexcom CGM will be provided. The Afrezza-Degludec group will continue to use Afrezza and insulin degludec for an additional 13 weeks in the Extension Phase classic.clinicaltrials.gov/ct2/show/NCT05904743 |
|
|
|
Post by castlerockchris on Mar 8, 2024 13:12:34 GMT -5
While not positive, I highly doubt ATTD holds any copyrights to presented material. My experience presenting at major expos such as this in other industries has never included signing over rights to my presented content. If this session was recorded ATTD could hold the copyright to that specific recording as content, but it would only apply to the use and distribution of that recording, not the material contained within (think of it as a song playing inside a movie. The composer retains their copywriter even though the movie itself is copyrighted) - which may be what you were thinking. Nobody would ever present anywhere if you were required to sign over the copyright to your content. There is a footnote on the slide, but nothing I did made them legible. My guess is those are standard attributions and sightings for the data.
|
|
|
|
Post by sayhey24 on Mar 8, 2024 13:14:18 GMT -5
sayhey ... find my house because my daughter and bf drink expensive bourbon. But, that's my$$$takeonit Hey man thanks - I appreciate that. I am pretty good at naming bourbons doing a tasting challenge. But I will be honest with being a Mannkind investor I usually go for quantity and not quality. Quantity is key being a MNKD investor. Don't get me wrong, if someone is offering a nice bourbon I am not turning it down but I will not turn Evan away from the door and he is 86 proof. George and Jack are only 80 unless I go white label and with the pps of MNKD I can't justify that for the quantity I need. |
|
|
|
Post by sayhey24 on Mar 8, 2024 13:16:43 GMT -5
While not positive, I highly doubt ATTD holds any copyrights to presented material. My experience presenting at major expos such as this in other industries has never included signing over rights to my presented content. If this session was recorded ATTD could hold the copyright to that specific recording as content, but it would only apply to the use and distribution of that recording, not the material contained within - which may be what you were thinking. Nobody would ever present anywhere if you were required to sign over the copyright to your content. There is a footnote on the slide, but nothing I did made them legible. My guess is those are standard attributions and sightings for the data. I asked IR if I can get a copy of the slides. I signed into ATTD but I don't see them anywhere but I am not the best at finding things. |
|
|
|
Post by mytakeonit on Mar 8, 2024 13:17:31 GMT -5
Not so ... I previously drank $150/bottle wine until the supplies ran out. The Castillo made me an official lifetime member.
But, that's mytakeonit
|
|
|
|
Post by cretin11 on Mar 8, 2024 13:27:34 GMT -5
Nothing wrong with Evan 86! Evan 1783 small batch a good value too.
|
|
|
|
Post by cretin11 on Mar 8, 2024 13:31:03 GMT -5
Nothing wrong with Evan 86! Evan 1783 small batch a good value too. Sayhey I suggest you try out New Riff distillery’s single barrel selections of rye and bourbon. Much higher price point than Evan but if we keep seeing this MNKD momentum it won’t be an issue 😀 |
|
|
|
Post by longliner on Mar 8, 2024 13:32:51 GMT -5
You should change nickname like harryx100 since you are even faster than Afrezza... This slide appears to show that Afrezza is the ONLY ULTRA Rapid Acting Insulin.
I assume once this is established, it will make Afrezza exclusive in this class. Insurance should then cover it as it is the only option in the class. SOC needs to catch up! So do the slower insulin's!  |
|
|
|
Post by ktim on Mar 8, 2024 13:34:06 GMT -5
Does Inhale-3 protocol allow/suggest/require follow up doses as needed? Thats what it says - lets hope they do corrections The Afrezza-Degludec group will inhale Afrezza at meals and corrections and will inject insulin degludec once a day for the 17 weeks of the RCT Phase. Dexcom CGM will be provided. The Afrezza-Degludec group will continue to use Afrezza and insulin degludec for an additional 13 weeks in the Extension Phase classic.clinicaltrials.gov/ct2/show/NCT05904743These 2 hour only results just don't seem that compelling to me. Seems an oversimplified take on that slide is that more aggressive dosing of RAA could have resulted in nearly the same 2 hour results as Afrezza, and that Afrezza group might be showing that they were starting to go higher at the end of 2 hours. Of course more aggressive RAA would presumably then start running into hypo risk that wouldn't show up within the two hour timeframe covered by these results. And any need for an Afrezza correction likewise isn't obvious. The full real world results from Inhale-3 would seem of much more interest. Good to see price holding up even as market took turn to the negative. |
|
|
|
Post by sayhey24 on Mar 8, 2024 13:49:54 GMT -5
Nothing wrong with Evan 86! Evan 1783 small batch a good value too. Sayhey I suggest you try out New Riff distillery’s single barrel selections of rye and bourbon. Much higher price point than Evan but if we keep seeing this MNKD momentum it won’t be an issue 😀 Maybe what we should do is meet up in Danbury on ASM day and if they don't let us in we can sit in the parking lot and we all bring a bottle of our favorite whiskey. I am not really a rye guy or scotch but as I said I am not turning much down for free. As a MNKD investor quantity is key. I have a pop up tent and tables/chairs I can throw in my truck. Then we can take some pictures and send them to Mike wishing he was "here". I can even bring my faded cooler and old afresa t-shirt. |
|
|
|
Post by prcgorman2 on Mar 8, 2024 13:53:10 GMT -5
Sayhey I suggest you try out New Riff distillery’s single barrel selections of rye and bourbon. Much higher price point than Evan but if we keep seeing this MNKD momentum it won’t be an issue 😀 Maybe what we should do is meet up in Danbury on ASM day and if they don't let us in we can sit in the parking lot and we all bring a bottle of our favorite whiskey. I am not really a rye guy or scotch but as I said I am not turning much down for free. As a MNKD investor quantity is key. I have a pop up tent and tables/chairs I can throw in my truck. Then we can take some pictures and send them to Mike wishing he was "here". I can even bring my faded cooler and old afresa t-shirt. Tailgate! |
|
|
|
Post by peppy on Mar 8, 2024 13:53:23 GMT -5
The two hour blood glucose level looks consistently nice and tapered over 2 hours.
Recall the dose study Mike did a couple of years ago?
My take on the slides, The dosing guidelines were sufficient for the two hour mark.
|
|
|
|
Post by sayhey24 on Mar 8, 2024 13:56:37 GMT -5
Thats what it says - lets hope they do corrections The Afrezza-Degludec group will inhale Afrezza at meals and corrections and will inject insulin degludec once a day for the 17 weeks of the RCT Phase. Dexcom CGM will be provided. The Afrezza-Degludec group will continue to use Afrezza and insulin degludec for an additional 13 weeks in the Extension Phase classic.clinicaltrials.gov/ct2/show/NCT05904743These 2 hour only results just don't seem that compelling to me. Seems an oversimplified take on that slide is that more aggressive dosing of RAA could have resulted in nearly the same 2 hour results as Afrezza, and that Afrezza group might be showing that they were starting to go higher at the end of 2 hours. Of course more aggressive RAA would presumably then start running into hypo risk that wouldn't show up within the two hour timeframe covered by these results. And any need for an Afrezza correction likewise isn't obvious. The full real world results from Inhale-3 would seem of much more interest. Good to see price holding up even as market took turn to the negative. More aggressive dosing of the RAA? At the Adcom I heard the FDA say that to that doctor who got great results in the 171 when he had his patients follow-up dose. She accused him of cheating and when she asked him why he didn't do that with the RAA arm he looked at her and said "I would have killed my patients". That lady was mad. Soon after they took a break and she was in the hallway fuming. I course the afrezza profile is going higher after 2 hours. Thats the power of afrezza. Its out of the system. If you need more take another puff just like Ginger V does. Thats what the pancreas does with second phase release. |
|
